You are currently viewing a new version of our website. To view the old version click .
Nanomaterials
  • Retraction
  • Open Access

12 January 2024

RETRACTED: Ahmed et al. Application of Nanopharmaceutics for Flibanserin Brain Delivery Augmentation Via the Nasal Route. Nanomaterials 2020, 10, 1270

,
,
,
,
,
,
,
,
and
1
Department of Pharmaceutics, Faculty of Pharmacy, King Abdulaziz University, Jeddah 21589, Saudi Arabia
2
Advanced Drug Delivery Research Group, Faculty of Pharmacy, King Abdulaziz University, Jeddah 21589, Saudi Arabia
3
Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Cairo University, Cairo 11562, Egypt
4
Department of Clinical Biochemistry, Faculty of Medicine, King Abdulaziz University, Jeddah 21589, Saudi Arabia
The Journal retracts the article “Application of Nanopharmaceutics for Flibanserin Brain Delivery Augmentation Via the Nasal Route” [1].
Following the publication, concerns were brought to the attention of the Editorial Office regarding the overlapping figures between publications [1,2], representing different experimental conditions. More specifically, subfigures B and D of Figure 6 in publication [2] are duplicated as subfigures D and C of Figure 6 in publication [1], respectively.
The authors cooperated with the investigation and commented that the mistake occurred while finalizing the figures for both studies, and the wrong image was selected for publication [1]. The authors also provided raw data and other documents related to the histopathological experiments in the reported study. However, the Editorial Board and Editor in Chief determined that the evidence and explanation provided were insufficient to justify the overlap observed, and inconsistencies in the raw data provided meant that serious doubts remained regarding the reliability of the data provided. As a result, the Editorial Board and Editor in Chief were unable to confirm the reliability of the findings and subsequently decided to retract this paper.
This retraction was approved by the Editor in Chief of the journal Nanomaterials.
The authors did not agree to this retraction.

References

  1. Ahmed, O.A.A.; Fahmy, U.A.; Badr-Eldin, S.M.; Aldawsari, H.M.; Awan, Z.A.; Asfour, H.Z.; Kammoun, A.K.; Caruso, G.; Caraci, F.; Alfarsi, A.; et al. RETRACTED: Application of Nanopharmaceutics for Flibanserin Brain Delivery Augmentation Via the Nasal Route. Nanomaterials 2020, 10, 1270. [Google Scholar] [CrossRef] [PubMed]
  2. Fahmy, U.A.; Ahmed, O.A.A.; Badr-Eldin, S.M.; Aldawsari, H.M.; Okbazghi, S.Z.; Awan, Z.A.; Bakhrebah, M.A.; Alomary, M.N.; Abdulaal, W.H.; Medina, C.; et al. RETRACTED ARTICLE: Optimized Nanostructured Lipid Carriers Integrated into In Situ Nasal Gel for Enhancing Brain Delivery of Flibanserin. Int. J. Nanomed. 2020, 15, 5253–5264. [Google Scholar] [CrossRef] [PubMed]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Article Metrics

Citations

Article Access Statistics

Multiple requests from the same IP address are counted as one view.